Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.37 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256315 | 0.90 | HSD17B1 (0.43) | HSD17B1HSD17B2P2RX7CCNA2CDK2 | |
| SCHEMBL5838165 | 0.90 | HSD17B1 (0.40) | HSD17B1HSD17B2P2RX7CCNA2CDK2 | |
| SCHEMBL5837478 | 0.86 | HSD17B1 (0.51) | HSD17B1HSD17B2P2RX7KCNA5AKT1 | |
| SCHEMBL5838979 | 0.84 | P2RX7 (0.45) | P2RX7CCNA2CDK2CCNA1CNR1 | |
| SCHEMBL5957075 | 0.84 | P2RX7 (0.45) | P2RX7CCNA2CDK2CCNA1CNR1 | |
| SCHEMBL1412884 | 0.83 | P2RX7 (0.62) | HSD17B1HSD17B2P2RX7AKT1NPC1 | |
| SCHEMBL5838248 | 0.81 | HSD17B1 (0.50) | HSD17B1HSD17B2P2RX7AKT1CNR1 | |
| SCHEMBL2181635 | 0.76 | HSD17B1 (0.48) | HSD17B1HSD17B2P2RX7KCNA5AKT1 | |
| SCHEMBL5838927 | 0.76 | HSD17B1 (0.42) | HSD17B1HSD17B2P2RX7KCNA5PDE2A | |
| SCHEMBL1412963 | 0.75 | P2RX7 (0.49) | HSD17B1HSD17B2P2RX7PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | DOMBROSKI MARK A | 2006-09-28 | — | — | US | disclosed |
| US-7071223-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1581507-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058731-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | HSD17B1 3394/4885HSD17B2 3943/4885P2RX7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.